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BiomarkerAnimal studies have shown that paraoxonase 1 (PON1) genotype can inﬂuence susceptibility to the organo-
phosphorus pesticide chlorpyrifos (CPF). However, Monte Carlo analysis suggests that PON1 genotype may
not affect CPF-related toxicity at low exposure conditions in humans. The current study sought to determine
the inﬂuence of PON1 genotype on the activity of blood cholinesterase as well as the effect of CPF exposure on
serum PON1 inworkers occupationally exposed to CPF. Saliva, blood and urinewere collected from agricultur-
al workers (n=120) from Egypt's Menouﬁa Governorate to determine PON1 genotype, blood cholinesterase
activity, serum PON1 activity towards chlorpyrifos-oxon (CPOase) and paraoxon (POase), and urinary levels of
the CPF metabolite 3,5,6-trichloro-2-pyridinol (TCPy). The PON1 55 (P≤0.05) but not the PON1 192 genotype
had a signiﬁcant effect on CPOase activity. However, both the PON1 55 (P≤0.05) and PON1 192 (P≤0.001)
genotypes had a signiﬁcant effect on POase activity. Workers had signiﬁcantly inhibited AChE and BuChE
after CPF application; however, neither CPOase activity nor POase activity was associated with ChE depression
when adjusted for CPF exposure (as determined by urinary TCPy levels) and stratiﬁed by PON1 genotype.
CPOase and POase activity were also generally unaffected by CPF exposure although there were alterations
in activity within speciﬁc genotype groups. Together, these results suggest that workers retained the capacity
to detoxify chlorpyrifos-oxon under the exposure conditions experienced by this study population regardless
of PON1 genotype and activity and that effects of CPF exposure on PON1 activity are minimal.
© 2012 Published by Elsevier Inc.Introduction
Organophosphorus pesticides (OPs) continue to be a human health
concern due to their worldwide use and documented human exposures
(Alexander et al., 2006; Farahat et al., 2010, 2011; Garabrant et al.,
2009). Human and animal studies consistently identify neurotoxicity
as the primary endpoint of concern (Bushnell and Moser, 2006; Costa,
2006). Determining the neurotoxic risks associated with occupational
exposure toOPs requires an understanding of not onlyworker exposure
levels, but also genetic susceptibility factors. With regard to the latter,artment of Pharmacology and
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, PON1 status does not inﬂue
012), http://dx.doi.org/10.1genetic polymorphisms in enzymes thatmetabolizeOPs arewidely pos-
ited to inﬂuence susceptibility to OP toxicity. Phosphorothioate OPs un-
dergo cytochrome P-450 (CYP)mediatedmetabolism to form an active,
highly toxic, oxon intermediate metabolite (Ma and Chambers, 1994)
which is the metabolite primarily responsible for the inhibition of not
only AChE, but also other B-esterases such as butyrylcholinesterase
(BuChE) and carboxylesterase (CE) (Sultatos, 1994). Detoxiﬁcation of
the active oxon metabolite primarily occurs by the A-esterase
paraoxonase 1 (PON1) (Pond et al., 1998; Sultatos and Murphy,
1983), an enzyme expressed mainly in the liver and secreted into the
blood. It has been proposed that inter-individual differences in PON1
can inﬂuence the rate of detoxiﬁcation of OPs, resulting in differences
in susceptibility to OP toxicity (Costa et al., 1999; Furlong et al., 2010).
Two common coding region polymorphisms in PON1 have been
identiﬁed: (1) a leucine/methionine amino acid polymorphism at
position 55 (PON1 L55M); and (2) a glutamine/arginine amino acid
polymorphisms at position 192 (PON1 Q192R) (Adkins et al., 1993).
The PON1 55 polymorphism affects PON1 mRNA (Leviev et al., 1997)
resulting in lower PON1 serum protein concentrations in individuals
with the M allele compared to the L allele (Garin et al., 1997). Thence cholinesterase activity in Egyptian agricultural workers exposed
016/j.taap.2012.08.031
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towards OPs in a substrate speciﬁc manner (Davies et al., 1996). In
vitro, the PON1 192R isoform hydrolyzes paraoxon and chlorpyrifos-
oxon faster than the PON1 192Q isoform; in contrast, PON1 192R and
192Q hydrolyze diazoxon at similar rates (Furlong et al., 2005; Li et
al., 2000). Similarly, in vivo studies demonstrate that intraperitoneal in-
jection of PON1 192R or PON1 192Q into PON1 knockout mice confers
a similar degree of protection against diazoxon intoxication, whereas
PON1 192R provides better protection against chlorpyrifos-oxon than
PON1 192Q (Li et al., 2000).
These observations have led to the proposal that PON1 status,which is
determined by the amount of PON1 protein present (inﬂuenced by PON1
55 genotype) and the activity of the enzyme (inﬂuenced by PON1 192
genotype), impacts individual susceptibility to OP toxicity (Furlong et
al., 2010; Hofmann et al., 2009; Li et al., 2000). The relationship between
PON1 genotype and symptoms associated with chronic OP toxicity has
been investigated in workers in the United Kingdom exposed to sheep
dip containing primarily diazinon (Cherry et al., 2002; Mackness et al.,
2003; Povey et al., 2005), farmers in India (Prabhavathy Das and Jamil,
2009), greenhouse workers in Spain (Hernandez et al., 2003) and South
African workers exposed to pesticides (Lee et al., 2003). Collectively,
these studies present conﬂicting results regarding an association between
PON1 genotype and worker health and in those studies that did ﬁnd an
association, there are discrepancies as to which genotype is more
sensitive to OP exposure. While these studies fail to provide a consensus
view on the value of PON1 status as a biomarker of susceptibility, it is dif-
ﬁcult to interpret what this means since OP exposures were determined
largely by job classiﬁcation and OP toxicity was based on symptoms asso-
ciated with but not unique to chronic OP toxicity. However, two recent
studies (Albers et al., 2010; Hofmann et al., 2009) that employed a more
speciﬁc biomarker of OP effect, blood cholinesterase activity, to address
the question of whether PON1 is a biomarker of susceptibility to OP
neurotoxicity yielded conﬂicting conclusions as well. The Hofmann et al.
(2009) study of agricultural pesticide applicators reported an inverse
association between PON1 activity and butyrylcholinesterase (BuChE)
activity; whereas the Albers et al. (2010) study of chlorpyrifos
manufacturing workers failed to ﬁnd an association between PON1
activity and either BuChE or acetylcholinesterase (AChE) activity. The
discrepancy between these two studies may reﬂect differences in the
OP exposure history between the two study populations, but the limited
exposure data available from the Hofmann et al. (2009) study precludes
rigorous assessment of this possibility.
We have been conducting a very detailed exposure assessment of
theMinistry of Agricultureworkerswhich apply pesticides in the cotton
ﬁelds in Egypt's Menouﬁa Governorate. Data collected during the sum-
mer of 2007 (Farahat et al., 2010) and 2008 (Farahat et al., 2011) dem-
onstrate signiﬁcant exposures to the OP, chlorpyrifos (CPF), in this
occupational cohort. In this study, we report data collected from a larger
cohort (n=120) recruited in 2009. Urinary 3,5,6-trichloro-2-pyridinol
(TCPy) levels were measured as a CPF-speciﬁc biomarker of exposure;
plasma BuChE and red blood cell (RBC) AChE activities were measured
as biomarkers of effect; and PON1 genotype (both Q192R and L55M
polymorphisms) and phenotype were investigated as potential
biomarkers of susceptibility. Samples were collected prior to, during
and after a cycle of daily CPF applications over 15 days, allowing us to
not only rigorously test the controversial hypothesis that PON1 status
inﬂuences human susceptibility to OP neurotoxicity in an occupational
cohort with clearly deﬁned exposures to a single OP, but to also test the
novel hypothesis that repeated CPF exposure modulates PON1 activity.
Materials and methods
Study setting and population. The study setting has been previously
described (Farahat et al., 2010). In brief, the study took place in
Menouﬁa, one of 29 governorates in Egypt, which is situated in the
Nile River delta north of Cairo. The Ministry of Agriculture controlsPlease cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1and oversees the use of pesticides and application procedures in cot-
ton ﬁelds throughout Egypt. Pesticide application is performed by
teams of workers employed by the Ministry of Agriculture consisting
of applicators who apply CPF to the cotton ﬁeld using backpack
sprayers, technicians who direct the direction of spray and the rate
at which applicators walk through the ﬁeld, and engineers who over-
see pesticide mixing and application to crops, often from the perime-
ter of the ﬁeld. It should be noted that none of these workers used
personal protective equipment to minimize dermal exposures. The
current study took place during the summer of 2009 and included
the ﬁrst cycle of CPF application. CPF was the only OP used during
this time period. All participants in the study were male Egyptians,
indigenous to the Nile delta region, with the vast majority being
born, raised and residing in Menouﬁa, Egypt at the time of the
study. Participants were between 14 and 69 years of age and had an
average body mass index of 26.9. Because certain disease states can
adversely inﬂuence the metabolism and excretion of TCPy, all
workers were questioned about prior diagnosis of diabetes mellitus
and liver or kidney disease by a physician during the recruitment pro-
cess. However, no exclusions for medical conditions were necessary.
Participants were asked to provide a urine and blood sample at two
different time points to monitor individuals for CPF exposure and
cholinesterase effects. The ﬁrst sample was collected at baseline two
to seven days prior to the period of daily CPF application. The second
sample was collected post-exposure, one to two days after a period of
up to 15 consecutive days of CPF application. For each time period,
urine and blood samples were collected on the same day for an individ-
ual and all participant samples were collected within ﬁve days of each
other. A total of 120 participants (96% agricultural workers) donated
saliva at enrollment and were included in the present study. Of these
120 participants, cholinesterase activity was determined for 100 partic-
ipants at baseline and 97 participants following CPF application. PON1
activity was determined for 67 participants who met the following
criteria: (1) the individual provided a saliva sample for PON1
genotyping; (2) the individual provided a plasma sample at baseline
and post CPF application; (3) the plasma sample was in good condition
(i.e., remained frozen and had little/no hemolysis); and (4) all samples
were clearly labeled. The protocol and consent forms used in this
research were approved by the Oregon Health and Science University
(USA) and Menouﬁa University (Egypt) Institutional Review Boards.
Subjects gavewritten informed consent prior to enrollment in the study.
Urine collection and TCPy analysis. A single spot urine specimen was
collected at the beginning of a given work day (2 pm) for assessing
TCPy as a biomarker of exposure, since previous studies conducted in
similar groups of Egyptian agriculture workers found that daily urinary
TCPy levels for a given worker were very similar in specimens collected
at the beginning (2–3 pm) and end (7–8 pm) of a given work day
(Farahat et al., 2010, 2011). After collection, samples were placed on
wet ice for transport to Menouﬁa University (Shebin El-Kom, Egypt).
Urine samples were subsequently aliquotted and stored at −20 °C
until shipped to the University at Buffalo (Buffalo, NY) on dry ice for
analysis. All urine samples were in good condition (i.e., remained
frozen) upon arrival to the University at Buffalo (Buffalo, NY). Urine
samples were analyzed for TCPy (the primary metabolite of CPF) by
negative-ion chemical ionization gas chromatography–mass spectrom-
etry, with 13C-15N-3,5,6-TCPy as an internal standard, as described pre-
viously (Farahat et al., 2010). Creatinine concentrations weremeasured
using the Jaffe reaction (Fabiny and Ertingshausen, 1971). Urinary TCPy
concentrations were expressed as μg TCPy/g creatinine. The within-run
imprecision for TCPy analysis was very low as shown by a b2% coefﬁ-
cient of variation and an intraclass correlation coefﬁcient between ana-
lytical replicates of 0.997 (Farahat et al., 2011).
Blood collection and analysis of BuChE and AChE activity. Blood sam-
ples were collected by venipuncture into 10 ml lavender top (15% K3nce cholinesterase activity in Egyptian agricultural workers exposed
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were then transported to Menouﬁa University (Shebin El-Kom, Egypt)
where they were analyzed in triplicate for AChE and BuChE activity
using an EQM Test-mate kit™ (Cincinnati, Ohio). The EQM Test-mate
kit™, based on the original Ellman method (Ellman et al., 1961), is a
portable photometric analyzer developed for the determination of cho-
linesterase activity in whole blood as a basis for monitoring pesticide
exposure (McConnell et al., 1992). The intraclass correlation coefﬁcient
for BuChE with this method was 0.987 and for AChE, 0.898, indicating
that there was very little within sample variation among replicates
relative to total variation (Farahat et al., 2011).
Analysis of PON1 genotype. Approximately 1–2 ml of saliva for each
subject was collected using an OG-250 saliva collection kit (DNA
Genotek Inc., Kanata, ON). Samples were transported to Menouﬁa
University (Shebin El-Kom, Egypt) where they were stored at room
temperature and shipped to the University at Buffalo for analysis.
Genomic DNA was isolated from saliva following the manufacturer's
instructions (DNA Genotek Inc., Kanata, ON). Puriﬁed DNA was stored
in TE buffer (10 mM Tris–HCl, 1 mM EDTA, pH 8.0) at −20 °C. PON1
55 and PON1 192 polymorphisms were determined by multiplex poly-
merase chain reaction (PCR) followed by restriction fragment length
polymorphism analysis as described previously (Motti et al., 2001).
The multiplex PCR reaction (25 μl) contained 12.5 μl of Qiagen Multi-
plex PCR buffer (Qiagen Inc., Valencia, CA), 0.2 μM of each primer,
9 μl of PCR grade water and approximately 0.5 μg of genomic DNA.
Thermocycle conditions were as follows: predenaturation at 95 °C for
15 min, 40 cycles of ampliﬁcation (94 °C for 1 min, 61 °C for 45 s,
72 °C for 45 s) and a ﬁnal extension at 72 °C for 10 min. PCR products
were digested in a restriction endonuclease mixture (20 μl) containing
10 μl of PCR product, 2 μl of REact 2 buffer (Invitrogen Inc., Carlsbad,
CA), 5 U of Hinf I (Invitrogen Inc., Carlsbad, CA) and 7.5 μl of distilled
water at 37 °C for 3 h. The digested products were separated by
electrophoresis on a 4% agarose gel containing ethidium bromide and
visualized on a UV transilluminator. Genotypes were determined by
the banding pattern of the digested products, where fragment sizes
were: 144 bp (PON1 55L), 122 bp (PON1 55M), 111 bp (PON1 192Q)
and 77 bp (PON1 192R).
Analysis of PON1 activity. Blood samples were collected by venipunc-
ture into 10 ml red top (no anticoagulant) vacutainer tubes and immedi-
ately placed on wet ice. Samples were then transported to Menouﬁa
University (Shebin El-Kom, Egypt) where clotted samples were
centrifuged and serum collected. Serum samples were subsequently
aliquotted and stored at −20 °C until shipped to the University at
Buffalo (Buffalo, NY) on dry ice for analysis. All serum samples were fro-
zen upon arrival to the University at Buffalo (Buffalo, NY). Frozen serum
was visually inspected for sample quality after storage and samples with
little/no hemolysis were included in the activity analysis. Serum PON1
activity towards chlorpyrifos-oxon (e.g., chlorpyrifosoxonase activity re-
ferred to as CPOase) and paraoxon (e.g., paraoxonase activity referred to
as POase)wasmeasured on a Cobas Fara II (Roche, Indianapolis, IN, USA)
chemistry analyzer as described previously (Browne et al., 2007; Furlong
et al., 1989). Assay conditions for CPOase activity consisted of buffer (0.1
Tris–HCl, 1 M NaCl, 2 mM CaCl2, pH 8.5), 320 μM chlorpyrifos-oxon
(ﬁnal concentration), and 5 μl of diluted serum (1:100 in 0.1 M Tris–
HCl, pH 8.5) in a ﬁnal volume of 303 μl. The composition of the buffer
was taken from Furlong et al. (1989). Hydrolysis of chlorpyrifos-oxon
by PON1 was monitored by the appearance of TCPy at 310 nm over
3 min. Assay conditions for POase activity consisted of buffer (50 mM
glycine, 1 mM CaCl2, pH 10.5), 1 mM paraoxon, and 20 μl diluted
serum (1:40 in 20 mM Tris–HCl, pH 8.0) in a ﬁnal volume of 300 μl.
The buffer for the POase assay was adapted from Eckerson et al., 1983
and a pH of 10.5 was conﬁrmed as being the optimal pH for POase activ-
ity. Hydrolysis of paraoxon by PON1wasmonitored by the appearance of
para-nitrophenol at 405 nm over 1.5 min. Quality control materialsPlease cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1consisting of frozen serum aliquots from two previously genotyped indi-
viduals (one PON1 192 QQ and one RR) were replicated in every run.
These quality control materials showed coefﬁcients of variation of
b9.1% for CPOase activity and b6.9% for POase activity assays. All samples
were analyzed in triplicate. The Cobas Fara II analyzer automatically con-
ducts a reagent diluent blankwith every analytical run. Blank absorbance
values are subtracted from all samples automatically by the analyzer
software to account for spontaneous hydrolysis of the substrate. PON1
activities were expressed as U/l (U=μmol of substrate hydrolyzed per
minute).
Statistical analysis. Allele and genotype frequencies for the SNPs
investigated were determined using the SNP and disease association
analysis software SNPAlyze (version 7, Dynacom Co. Ltd., Yokohama,
Japan). The normalized linkage disequilibrium coefﬁcient D′ was also
determined by the SNPAlyze software. The Hardy–Weinberg equilib-
rium was tested for the study population by the chi-squared test and
was not rejected. Differences between baseline and post CPF expo-
sure measures for individuals of the same genotype were determined
using the paired t-test for parametric data (plasma BuChE, RBC AChE,
CPOase and POase) and the Wilcoxon signed rank test for non-
parametric data (urinary TCPy). Differences in PON1 activity between
PON1 genotypes for the same time period were determined by ANOVA
with Tukey's post-hoc test. PON1 genotype and activity were investigat-
ed as potential modiﬁers of CPF toxicity by using the percent change in
BuChE activity between baseline and post-spray levels as a sensitive bio-
marker of effect. Percent change was calculated as (BuChEbaseline−
BuChEpost/BuChEbaseline)∗100. The degree of change in BuChE activity
was used in order to eliminate effects of the interindividual variability
of baseline BuChE activity. Linear regression analysis was performed
with baseline serum PON1 CPOase activity modeled as a continuous
predictor of BuChE inhibition after stratiﬁcation by L55Mor Q192R geno-
type. Linear regression analysis was also performed with baseline serum
PON1 POase activity modeled as a continuous predictor of BuChE inhibi-
tion after stratiﬁcation by L55M or Q192R genotypes. The analysis was
repeated in all cases after adjustment for urinary TCPy concentration
(post exposure TCPyminus pre exposure TCPy; marker of CPF exposure)
as a covariate. Analyses were done using SPSS statistical software (Chica-
go, IL). A P-value≤0.05was deemed statistically signiﬁcant unless other-
wise noted.
Results
Urinary TCPy and blood ChE
Baseline and post CPF application urinary TCPy concentrations are
shown in Table 1. At baseline, there was a wide range in urinary TCPy
concentrations (1.5 to 734 μg/g creatinine) with the median urinary
TCPy concentration being 7.0 μg/g creatinine. Following the CPF
application period, urinary TCPy concentration was signiﬁcantly
increased with the median urinary TCPy concentration being
15.9 μg/g creatinine. There was a broad range in BuChE activity at base-
line (0.49 to 3.65 U/ml) and post CPF application (0.39 to 2.82 U/ml).
BuChE activity was signiﬁcantly decreased following CPF application
(Table 1 and Supplemental Table 1). Therewas also a statistically signif-
icant decrease in AChE activity following CPF application (Table 1 and
Supplemental Table 1). An inverse correlation was observed between
urinary TCPy and plasma BuChE but not between urinary TCPy and
RBC AChE (Supplemental Fig. 1).
PON1 genotype
PON1 gene frequencies for the Egyptian study population were
determined for PON1 55 and PON1 192 (Table 2). All genotypes
were consistent with Hardy–Weinberg equilibrium. The haplotype
combinations were QR/LM (25%), QQ/LM (18%), QR/LL (17%), RR/LLnce cholinesterase activity in Egyptian agricultural workers exposed
016/j.taap.2012.08.031
Table 1
Urinary TCPy concentration, blood cholinesterase activity, and plasma PON1 activity
from the Egyptian study population before and after CPF application.
Measure Baseline Post CPF application P-value
Urinary TCPy (μg/g creatinine)
N 100 97 b0.001a
Mean±SD 18.4±73.4 49.1±177.8
Median 7.0 15.9
Range 1.5–734 2.9–1664
Plasma BuChE (U/ml)
N 100 97 b0.001b
Mean±SD 1.77±0.52 1.59±0.52
Median 1.75 1.64
Range 0.49–3.65 0.36–2.82
RBC AChE (U/g Hgb)
N 100 97 0.018b
Mean±SD 28.3±3.5 27.7±3.2
Median 28.4 26.8
Range 11.7–37.3 19.0–37.5
CPOase (U/l)
N 67 67 0.398b
Mean±SD 3680±1140 3772±1216
Median 3668 3829
Range 1286–6348 1329–7030
POase (U/l)
N 67 67 0.053b
Mean±SD 83.5±39.3 78.3±35.2
Median 77.4 73.4
Range 23.8–171.2 18.0 - 173.4
P-value compares measures collected at baseline to post CPF application using aWilcoxon
sign rank test or bpaired t-test.
4 C.A. Ellison et al. / Toxicology and Applied Pharmacology xxx (2012) xxx–xxx(13%), QQ/MM (12%), QQ/LL (11%) QR/MM (4%) and RR/LM (1%). The
haplotype combination of RR/MM did not occur in the study popula-
tion. In this population, the 192R allele and the 55L allele are in strong
linkage disequilibrium (D′=−0.7463).
PON1 activity
Serum PON1 CPOase and POase activities were determined at
baseline and post CPF application (Table 1). No signiﬁcant difference
was observed in the total population between PON1 activity (CPOase
or POase) at baseline versus post CPF exposure. However, when the
population was stratiﬁed by genotype, (PON1 55 or PON1 192), a sta-
tistically signiﬁcant (P=0.048) increase in CPOase activity post CPF
exposure was observed for the PON1 192 RR genotype and a statisti-
cally signiﬁcant (P=0.018) decrease in POase activity was observedTable 2
PON1 allele and genotype frequencies in the Egyptian study population.
PON1 L55M Number of individuals (total=120) Frequency
Genotype
LL 49 40.8
LM 52 43.3
MM 19 15.8
Allele
L 62.5
M 37.5
PON1 Q192R
Genotype
QQ 48 40.0
QR 55 45.8
RR 17 14.2
Allele
Q 62.9
R 37.1
Please cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1for the PON1 192 QR genotype. No signiﬁcant difference was
observed between baseline and post CPF application PON1 activity
for all other genotypes.
Mean CPOase activity was signiﬁcantly different between the
three different PON1 55 genotypes (Fig. 1 and Table 3). Individuals
with the PON1 55 LL genotype had the highest average CPOase
activity (baseline, 4223 U/l) while individuals with the PON1 55
MM genotype had the lowest average CPOase activity (baseline,
2205 U/l). Even though signiﬁcant differences in average CPOase
activity were seen among the different PON1 55 genotypes, there
was still a wide range of activities within a given genotype. No signiﬁ-
cant difference was observed in average CPOase activity among the
different PON1 192 genotypes. When stratifying CPOase activity by
PON1 55 and PON1 192 genotype there was still a large range in
average activity; however, the highest average activity was observed
in individuals with the PON1 LL/QQ and PON1 LL/QR genotypes while
the lowest average activity was from individuals with the PON1 MM/
QQ and PON1 MM/QR genotypes (Table 4).
With regard to POase activity, individuals with the PON1 55 LL
genotype had signiﬁcantly higher average activity compared to indi-
viduals with the PON1 55 MM genotype (Fig. 1 and Table 3). Further-
more, individuals with the PON1 192 QQ genotype had signiﬁcantly
less average POase activity than those with the PON1 192 RR genotype.
Similar to CPOase activity, there was a wide range in POase activity
within a given PON1 genotype. The highest average POase activity
and the lowest average POase activity were from individuals with the
PON1 LL/RR and PON1 MM/QR genotype, respectively.
Relationship between serum PON1 and blood BuChE activity
BuChE is more susceptible to chlorpyrifos-oxon inhibition than
AChE (Amitai et al., 1998) and greater BuChE inhibition post CPF
exposure was observed in our population as compared to AChE
(Table 1 and Supplemental Table 1). Therefore, BuChE activity was
used as a sensitive marker of potential CPF toxicity. The percentage
change in BuChE from baseline to post CPF application was calculated
and used to minimize the effects of variability in BuChE activity be-
tween individuals. Serum POase activity was modeled as a predictor
of BuChE activity after stratifying by PON1 genotype (L55M or
Q192R) both with and without adjustment for CPF exposure level
(as measured by post exposure TCPy minus pre exposure TCPy). No
signiﬁcant correlation between PON1 POase activity and BuChE
inhibition was seen within any of the genotypes with or without
adjustment for exposure (data not shown). CPOase activity was simi-
larly modeled against BuChE activity (Fig. 2). No signiﬁcant correlation
between PON1 CPOase activity and BuChE inhibition was seen within
any of the genotypes with or without adjustment for exposure
(Table 5).
Discussion
It remains controversial as to whether PON1 genotype inﬂuences
OP neurotoxicity in humans. Not all the studies performed to date
have identiﬁed an association between PON1 status and either blood
cholinesterase activity (Albers et al., 2010) or symptoms associated
with but not necessarily speciﬁc to chronic OP neurotoxicity
(Hernandez et al., 2003), and among those studies that have reported
an association between PON1 genotype and worker health, there
have been conﬂicting results as to which genotype is more sensitive
to OP exposure (Hofmann et al., 2009; Mackness et al., 2003). It is
not clear whether the conﬂicting ﬁndings in the current literature
reﬂect differences in the study populations, differences in exposure
histories (including types, duration and levels of OP exposures) or the
failure to include both PON1 genotype and phenotype in the analysis.
The current study was conducted using an occupational cohort with a
clearly deﬁned CPF exposure and longitudinal measures of TCPy, ance cholinesterase activity in Egyptian agricultural workers exposed
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Fig. 1. Baseline and post CPF application CPOase (top panels) and POase (bottom panels) activities based on the PON1 polymorphism at position 55 (left panels) and position 192
(right panels).
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of effect, and PON1 genotype and phenotype before and after CPF ex-
posure; thereby, enabling conclusions to be drawn about the role of
PON1 as a susceptibility factor for OP neurotoxicity in a deﬁned expo-
sure scenario and population.
Application of CPF to cotton ﬁelds was associated with a signiﬁ-
cant exposure of agriculture workers based on urinary TCPy levels,
which provide a sensitive and speciﬁc biomarker of exposure to CPF
(Table 1). Urinary TCPy concentration in study cohort from 2009
ranged from 1.5 to 1664 μg/g creatinine, while previous studies of
Egyptian agricultural workers involved in CPF application have
reported concentrations from approximately 20 to 2000 μg/g creati-
nine in 2007 (Farahat et al., 2010) and 10 to 10,000 μg/g creatinine
in 2008 (Farahat et al., 2011). Some workers had elevated urinary
TCPy levels at baseline which has been explained by the episodic
use of pesticides outside of their ministry jobs (Farahat et al., 2011).
Application of CPF to the ﬁelds was also associated with a statisti-
cally signiﬁcant decrease in blood BuChE and AChE activity (Table 1).
It is notable that although the 2009 study population had lower CPFTable 3
Serum PON1 activity towards chlorpyrifos-oxon and paraoxon stratiﬁed by PON1 genotype
PON1 genotype N CPOase (U/l)
Baseline P
PON1 L55M
LL 34 4223 (1966–6348) 4
LM 25 3415 (1592–5494)a 3
MM 8 2205 (1286–2842)b,c 2
PON1 Q192R
QQ 25 3607 (1941–5982) 3
QR 29 3722 (1286–6348) 3
RR 13 3731 (1592–4643) 3
Data expressed as the mean (range). P-value compares CPOase or POase activity among the
Tukey post-hoc test.
a P≤0.05 compared to the PON1 55 LL genotype.
b P≤0.001 compared to the PON1 55 LL genotype.
c P≤0.05 compared to the PON1 55 LM genotype.
d P≤0.001 compared to the PON1 192 QQ genotype.
e P≤0.001 compared to the PON1 192 QQ and QR genotypes.
Please cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1exposures on average relative to the study populations in previous
years as documented in Farahat et al. (2010, 2011), there remains a
consistent decrease in AChE and BuChE activity for these workers.
Of the workers for whom samples were collected for cholinesterase
measures, CPF application was associated with a signiﬁcant decrease
in BuChE relative to baseline in 70 of 90 while 58 of 90 experienced
signiﬁcantly decreased AChE (Supplemental Table 1). However, few
individuals had BuChE depression of more than 40% inhibition and
there were no cases of AChE greater than 30% inhibition, which are
the levels of cholinesterase inhibition proposed to be biologically
signiﬁcant (Furman, 2010; Ngai et al., 2002). As expected given
these ﬁndings, none of the workers were clinically symptomatic.
Normal reported values for the EQM Test-mate™ for whole blood
AChE and BuChE are 27.1±2.9 U/g Hgb and 2.03±0.40 U/ml, respec-
tively. Even though AChE in the currently study population displayed
a signiﬁcant decrease post-exposure (27.7±3.2 U/g Hgb), levels
remained within the normal range for this assay. In contrast, even at
baseline, mean BuChE activity in this study population (1.77±
0.52 U/ml) was at the low end of this range. Additionally, there was a.
POase (U/l)
ost CPF exposure Baseline Post CPF exposure
262 (1858–7030) 98 (36–171) 94 (36–173)
508 (1507–6607)a 76 (24–132) 69 (18–121)a
511 (1329–3992)b 45 (31–77)b 41 (32–69)b,c
981 (1606–7030) 49 (24–86) 50 (18–87)
504 (1329–5277) 92 (46–149)d 82 (32–124)d
965 (1507–5301) 131 (59–171)e 125 (42–173)e
different PON1 55 or PON1 192 genotypes for the same time period using ANOVA with
nce cholinesterase activity in Egyptian agricultural workers exposed
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Table 4
Serum PON1 activity towards chlorpyrifos-oxon and paraoxon respective to PON1 55 and PON1 192 genotype.
PON1 genotype N CPOase (U/l) POase (U/l)
Baseline Post CPF exposure Baseline Post CPF exposure
QQ/LL 11 4196 (2854–5982) 4601 (2977–7030) 54 (36–86) 58 (36–81)
QQ/LM 9 3552 (2010–5494) 3779 (1606–6607) 47 (24–63)a,b 46 (18–87)a,b
QQ/MM 5 2411 (1941–2842)a,b,c 2982 (2380–3992) 38 (31–42)a,b,d 38 (32–46)a,b,e
QR/LL 11 4593 (1966–6348) 4024 (1858–5277) 100 (61–149)c 88 (59–124)c
QR/LM 15 3455 (2262–5053)a 3478 (2152–4924) 94 (56–132)b,c,e 85 (61–121)b,c,e
QR/MM 3 1860 (1286–2345)a,b,c 1727 (1329–2474)a,b,c 57 (46–77)b 47 (32–69)a,b,e
RR/LL 12 3909 (2269–4643) 4170 (2680–5301) 136 (59–171)a,c 132 (101–173)a,c
RR/LM 1 1592 1507 78 42
RR/MM 0 – – – –
Data expressed as the mean (range). P-value compares CPOase or POase activity among the different genotypes for the same time period using ANOVA with Tukey post-hoc test.
a P≤0.05 compared to QRLL genotype.
b P≤0.05 compared to RRLL genotype.
c P≤0.05 compared to QQLL genotype.
d P≤0.05 compared to QRLM genotype.
e P≤0.05 compared to QQLM genotype.
6 C.A. Ellison et al. / Toxicology and Applied Pharmacology xxx (2012) xxx–xxxwide range in BuChE activity at baseline, which was not unexpected
given the normal variation in BuChE activity. BuChE activity can vary
with bodymass index, age, lipid and cholesterol levels, and serum albu-
min (Calderon-Margalit et al., 2006; Sklan et al., 2004). In this case,
differences in home pesticide use and other outside exposure scenarios
are no doubt also contributing to varying baseline activity among
individual agricultural workers. This wide range of baseline activity
emphasizes the usefulness ofmonitoringworkers over a season relative
to their own baseline in order to characterize occupational exposure.
Collectively, however, these data indicate that individuals in our study
population exhibit variable exposures and responses to CPF exposures,
which provides a rich dataset for testing an association between PON1
status and susceptibility to OP toxicity.
The 192R allele and the 55L allele are in linkage disequilibrium to
varying degrees in different populations. In Caucasian populations,
the 192R/55M genotype is rarely found (Garin et al., 1997) while in
Brazilians of African descent, this linkage disequilibrium is not as
strong (Allebrandt et al., 2002). In our population, the 192R allele and
the 55L allele are in strong linkage disequilibrium (D′=0.7463). TheFig. 2. BuChE inhibition in relation to CPOase activity, s
Please cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1allele frequencies for the variant 192R in our study population of
Egyptian males are similar to the reported frequencies for Egyptian fe-
males (N=100) (Hussein et al., 2011), though the frequency for the
55M allele we observed in the male agricultural workers (37%) was
lower than that reported in the female Egyptian population (53.5%).
The current study determined PON1 activity prior to and following
15 consecutive days of CPF application. This provided the opportunity
to test the hypothesis that repeated CPF exposures modify PON1
activity. There is signiﬁcant experimental evidence that OPs can alter
the activity of diverse enzymes (Casida and Quistad, 2005; Grigoryan
et al., 2009; Lockridge and Schopfer, 2010; Ruark et al., 2011), so it is
not inconceivable that either CPF or its oxon metabolite might alter
the structure or function of PON1 or induce PON1 activity as a compen-
satory mechanism. If repeated CPF exposure altered PON1 activity, this
might suggest not only an explanation of the discrepant ﬁndings be-
tween the Albers et al. (2010) and Hofmann et al. (2009) studies, but
if PON1 activity were upregulated by repeated CPF exposure, it would
suggest a compensatory mechanism to explain our earlier observation
that Egyptian agricultural workers with repeated high exposures to CPFtratiﬁed by PON1 L55M or PON1 Q192R genotype.
nce cholinesterase activity in Egyptian agricultural workers exposed
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Table 5
Results of linear regression model of CPOase activity as a predictor of BuChE inhibition
stratiﬁed by PON1 55 or 192 genotype.
PON1 genotype N Unadjusted Adjusteda
β Coefﬁcient P-value β Coefﬁcient P-value
LL 31 0.001 0.837 0.003 0.489
LM 24 0.005 0.118 0.006 0.105
MM 7 −0.011 0.058 −0.011 0.061
QQ 23 0.003 0.497 0.004 0.231
QR 26 0.004 0.435 0.006 0.186
RR 13 −0.008 0.432 −0.010 0.351
The β coefﬁcient is based on linear regression analysis and represents the unit change
in BuChE attributable to a unit change in CPOase activity.
a Urinary TCPy included as a covariate.
7C.A. Ellison et al. / Toxicology and Applied Pharmacology xxx (2012) xxx–xxxand greatly inhibited AChE nevertheless show no overt signs of toxicity
(Farahat et al., 2011). In the current study, similar PON1 activities
(CPOase and POase) were observed at baseline and post CPF exposure
for the entire population (Table 1). However, when PON1 activity was
stratiﬁed by genotype there was a statistically signiﬁcant increase in
CPOase activity post CPF exposure for the PON1 192 RR genotype and
a signiﬁcant decrease in POase activity for the PON1 192 QR genotype.
It is not clear whether this is linked to a particular genotype or driven
by a few individuals experiencing an increase in CPOase activity or a
decrease in POase activity over the CPF application period; however,
it is possible that CPF exposure may cause slight variations in PON1
activity within an individual. But, since we were ultimately not able
to detect a relationship between CPOase or POase activity and cholines-
terase inhibition (see below), it suggests that these subtle changes in
an individual may not have a large overall impact on CPF metabolism
and toxicity. It should also be noted that PON1 activity can vary up to
40-fold within a given population and protein levels can vary up to
13-fold for a single PON1 192 genotype (Costa et al., 2005) and the
slight detected changes in response to CPF exposure seen in the current
study do not alter activity outside the normal range for a particular ge-
notype group.
We found that human serum PON1 activity towards chlorpyrifos-
oxon, e.g. CPOase activity, is signiﬁcantly associated with PON1 55
genotype but not PON1 192 genotype. Our ﬁndings for PON1 55 are
consistent with results from Holland et al. (2006); whereas the lack
of association we observed between PON1 192 genotype and CPOase
activity differs from that of Holland et al. (2006) but is consistent
with ﬁndings from Albers et al. (2010). The Albers population is more
similar to our population in that they are predominantly adult males
occupationally exposed to CPF while the Holland study population is
very different in that it consists of pregnant women and newborns
exposed to environmental levels of OPs. With regard to the PON1 55
genotype, even though a signiﬁcant relationship was observed be-
tween genotype and average CPOase activity, a wide range in activity
still existed within a genotype. In some cases, individuals with a low
activity genotype (PON1 55 MM) had approximately twice as much
CPOase activity than an individual with a high activity genotype
(PON1 55 LL). This is in agreement with previous reports that genotype
alone is insufﬁcient to determine an individual's potential to hydrolyze
chlorpyrifos-oxon (Brophy et al., 2000; Costa et al., 2005; Furlong et al.,
2010; Povey, 2010; Richter and Furlong, 1999).
Our ﬁndings support the conclusion that PON1 genotype does not
impact BuChE or AChE activity. Furthermore, unlike the previous
human studies, we also examined the change in CPOase activity and
POase activity from baseline to post exposure which has never been
done before and included the PON1 L55M genotype in our analysis in
addition to the more commonly studied PON1 Q192R polymorphism.
In the current study, even though individuals among the different
PON1 55 genotypes had signiﬁcant differences in CPOase activity, this
did not signiﬁcantly affect BuChE or AChE inhibition at CPF exposurePlease cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1levels experienced by the study population. Monte Carlo analysis
suggest that PON1 genotype may not affect CPF- related toxicity at
low exposure conditions but may become an important determinant
in CPF sensitivity at higher CPF exposures (Timchalk et al., 2002).
Future studies with deﬁned exposures are needed to determine if the
relative inﬂuence of PON1 genotype on CPF-toxicity is greater in a
more highly exposed population.
In summary, the present study utilized urinary TCPy concentrations
as a biomarker of CPF exposure and conﬁrmed that Egyptian agricul-
tural workers experience occupational exposures to CPF during CPF ap-
plication to cotton ﬁelds. Following CPF exposure, there was a
statistically signiﬁcant decrease in plasma BuChE and RBC AChE activi-
ties among the workers, a signiﬁcant decrease in POase activity in the
PON1 192 QR group and a signiﬁcant increase in CPOase activity in
the PON1 192 RR group. However, these changes were relatively subtle
given the inherent biological variability of these enzymes. The PON1 55
but not the PON1 192 genotype signiﬁcantly affected an individual's
ability to hydrolyze chlorpyrifos-oxon but neither genotype nor
CPOase activity had a signiﬁcant effect on plasma BuChE or red blood
cell AChE inhibition. Together this suggests that regardless of PON1 ge-
notype and activity the workers retained the capacity to detoxify
chlorpyrifos-oxon under the exposure conditions experienced by this
study population.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.taap.2012.08.031.Conﬂict of interest
There are no conﬂicts of interest.Acknowledgments
We thank Steve Hutton (Dow Agrosciences, Indianapolis, IN) for
providing 13C–15N‐3,5,6-TCP, and the Egyptian Ministry of Agriculture.
Barb McGarrigle (University of Buffalo) analyzed the urine samples.
This work was supported by the National Institute of Environmental
Health Sciences (NIEHS) [grant number ES016308]. Corie Ellison was
supported by a Research Supplement to Promote Diversity in Health-
Related Research from the NIEHS [grant number ES016308-02S].
Alice Crane was supported by a Ruth L. Kirschstein National Research
Service Award from the NIEHS [grant number F30 ES020655]. The
content is solely the authors' responsibility and does not necessarily
represent ofﬁcial views of NIEHS.References
Adkins, S., Gan, K.N., Mody, M., La Du, B.N., 1993. Molecular basis for the polymorphic
forms of human serum paraoxonase/arylesterase: glutamine or arginine at position
191, for the respective A or B allozymes. Am. J. Hum. Genet. 52, 598–608.
Albers, J.W., Garabrant, D.H., Berent, S., Richardson, R.J., 2010. Paraoxonase status and
plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers.
J. Expo. Sci. Environ. Epidemiol. 20, 79–89.
Alexander, B.H., Burns, C.J., Bartels, M.J., Acquavella, J.F., Mandel, J.S., Gustin, C., Baker,
B.A., 2006. Chlorpyrifos exposure in farm families: results from the farm family
exposure study. J. Expo. Sci. Environ. Epidemiol. 16, 447–456.
Allebrandt, K.V., Souza, R.L., Chautard-Freire-Maia, E.A., 2002. Variability of the
paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol. Appl. Pharmacol.
180, 151–156.
Amitai, G., Moorad, D., Adani, R., Doctor, B.P., 1998. Inhibition of acetylcholinesterase
and butyrylcholinesterase by chlorpyrifos-oxon. Biochem. Pharmacol. 56,
293–299.
Brophy, V.H., Jarvik, G.P., Richter, R.J., Rozek, L.S., Schellenberg, G.D., Furlong, C.E., 2000.
Analysis of paraoxonase (PON1) L55M status requires both genotype and pheno-
type. Pharmacogenetics 10, 453–460.
Browne, R.W., Koury, S.T., Marion, S., Wilding, G., Muti, P., Trevisan, M., 2007. Accuracy
and biological variation of human serum paraoxonase 1 activity and polymorphism
(Q192R) by kinetic enzyme assay. Clin. Chem. 53, 310–317.
Bushnell, P.J., Moser, V.C., 2006. Behavioral toxicity of cholinesterase inhibitors. In:
Gupta, R.C. (Ed.), Toxicology of Organophosphate and Carbamate Compounds.
Elsevier, San Diego, pp. 347–360.nce cholinesterase activity in Egyptian agricultural workers exposed
016/j.taap.2012.08.031
8 C.A. Ellison et al. / Toxicology and Applied Pharmacology xxx (2012) xxx–xxxCalderon-Margalit, R., Adler, B., Abramson, J.H., Goﬁn, J., Kark, J.D., 2006.
Butyrylcholinesterase activity, cardiovascular risk factors, and mortality in middle-
aged and elderly men and women in Jerusalem. Clin. Chem. 52, 845–852.
Casida, J.E., Quistad, G.B., 2005. Serine hydrolase targets of organophosphorus toxicants.
Chem. Biol. Interact. 157–158, 277–283.
Cherry, N., Mackness, M., Durrington, P., Povey, A., Dippnall, M., Smith, T., Mackness, B.,
2002. Paraoxonase (PON1) polymorphisms in farmers attributing ill health to
sheep dip. Lancet 359, 763–764.
Costa, L.G., 2006. Current issues in organophosphate toxicology. Clin. Chim. Acta 366,
1–13.
Costa, L.G., Li, W.F., Richter, R.J., Shih, D.M., Lusis, A., Furlong, C.E., 1999. The role of
paraoxonase (PON1) in the detoxication of organophosphates and its human poly-
morphism. Chem. Biol. Interact. 119–120, 429–438.
Costa, L.G., Vitalone, A., Cole, T.B., Furlong, C.E., 2005. Modulation of paraoxonase
(PON1) activity. Biochem. Pharmacol. 69, 541–550.
Davies, H.G., Richter, R.J., Keifer, M., Broomﬁeld, C.A., Sowalla, J., Furlong, C.E., 1996. The
effect of the human serum paraoxonase polymorphism is reversed with diazoxon,
soman and sarin. Nat. Genet. 14, 334–336.
Eckerson, H.W., Wyte, C.M., La Du, B.N., 1983. The human serum paraoxonase/
arylesterase polymorphism. Am. J. Hum. Genet. 35, 1126–1138.
Ellman, G.L., Courtney, K.D., Andres Jr., V., Feather-Stone, R.M., 1961. A new and rapid
colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol.
7, 88–95.
Fabiny, D.L., Ertingshausen, G., 1971. Automated reaction-rate method for determination
of serum creatinine with the CentriﬁChem. Clin. Chem. 17, 696–700.
Farahat, F.M., Fenske, R.A., Olson, J.R., Galvin, K., Bonner, M.R., Rohlman, D.S., Farahat,
T.M., Lein, P.J., Anger, W.K., 2010. Chlorpyrifos exposures in Egyptian cotton ﬁeld
workers. Neurotoxicology 31, 297–304.
Farahat, F.M., Ellison, C.A., Bonner, M.R., McGarrigle, B.P., Crane, A.L., Fenske, R.A.,
Lasarev, M.R., Rohlman, D.S., Anger, W.K., Lein, P.J., Olson, J.R., 2011. Biomarkers
of chlorpyrifos exposure and effect in Egyptian cotton ﬁeld workers. Environ.
Health Perspect. 119, 801–806.
Furlong, C.E., Richter, R.J., Seidel, S.L., Costa, L.G., Motulsky, A.G., 1989. Spectrophoto-
metric assays for the enzymatic hydrolysis of the active metabolites of chlorpyrifos
and parathion by plasma paraoxonase/arylesterase. Anal. Biochem. 180, 242–247.
Furlong, C.E., Cole, T.B., Jarvik, G.P., Pettan-Brewer, C., Geiss, G.K., Richter, R.J., Shih,
D.M., Tward, A.D., Lusis, A.J., Costa, L.G., 2005. Role of paraoxonase (PON1) status
in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology 26,
651–659.
Furlong, C.E., Suzuki, S.M., Stevens, R.C., Marsillach, J., Richter, R.J., Jarvik, G.P.,
Checkoway, H., Samii, A., Costa, L.G., Grifﬁth, A., Roberts, J.W., Yearout, D.,
Zabetian, C.P., 2010. Human PON1, a biomarker of risk of disease and exposure.
Chem. Biol. Interact. 187, 355–361.
Furman, J., 2010. Cholinesterase Monitoring for Agricultural Pesticide Handlers: Guidelines
for Health Care Providers in Washington State. Department of Labor and Industries
Division of Occupational Safety and Health (DOSH).
Garabrant, D.H., Aylward, L.L., Berent, S., Chen, Q., Timchalk, C., Burns, C.J., Hays, S.M.,
Albers, J.W., 2009. Cholinesterase inhibition in chlorpyrifos workers: characteriza-
tion of biomarkers of exposure and response in relation to urinary TCPy. J. Expo.
Sci. Environ. Epidemiol. 19, 634–642.
Garin, M.C., James, R.W., Dussoix, P., Blanche, H., Passa, P., Froguel, P., Ruiz, J., 1997.
Paraoxonase polymorphism Met-Leu54 is associated with modiﬁed serum
concentrations of the enzyme. A possible link between the paraoxonase gene
and increased risk of cardiovascular disease in diabetes. J. Clin. Invest. 99, 62–66.
Grigoryan, H., Schopfer, L.M., Peeples, E.S., Duysen, E.G., Grigoryan, M., Thompson, C.M.,
Lockridge, O., 2009. Mass spectrometry identiﬁes multiple organophosphorylated
sites on tubulin. Toxicol. Appl. Pharmacol. 240, 149–158.
Hernandez, A.F., Mackness, B., Rodrigo, L., Lopez, O., Pla, A., Gil, F., Durrington, P.N.,
Pena, G., Parron, T., Serrano, J.L., Mackness, M.I., 2003. Paraoxonase activity and ge-
netic polymorphisms in greenhouse workers with long term pesticide exposure.
Hum. Exp. Toxicol. 22, 565–574.
Hofmann, J.N., Keifer, M.C., Furlong, C.E., De Roos, A.J., Farin, F.M., Fenske, R.A., van
Belle, G., Checkoway, H., 2009. Serum cholinesterase inhibition in relation to
paraoxonase-1 (PON1) status among organophosphate-exposed agricultural pesti-
cide handlers. Environ. Health Perspect. 117, 1402–1408.Please cite this article as: Ellison, C.A., et al., PON1 status does not inﬂue
to chlorpyrifos, Toxicol. Appl. Pharmacol. (2012), http://dx.doi.org/10.1Holland, N., Furlong, C., Bastaki, M., Richter, R., Bradman, A., Huen, K., Beckman, K.,
Eskenazi, B., 2006. Paraoxonase polymorphisms, haplotypes, and enzyme activity
in Latino mothers and newborns. Environ. Health Perspect. 114, 985–991.
Hussein, Y.M., Gharib, A.F., Etewa, R.L., ElSawy, W.H., 2011. Association of L55M and
Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk
and their clinical signiﬁcance. Mol. Cell. Biochem. 351, 117–123.
Lee, B.W., London, L., Paulauskis, J., Myers, J., Christiani, D.C., 2003. Association between
human paraoxonase gene polymorphism and chronic symptoms in pesticide-
exposed workers. J. Occup. Environ. Med. 45, 118–122.
Leviev, I., Negro, F., James, R.W., 1997. Two alleles of the human paraoxonase gene
produce different amounts of mRNA. An explanation for differences in serum con-
centrations of paraoxonase associated with the (Leu-Met54) polymorphism.
Arterioscler. Thromb. Vasc. Biol. 17, 2935–2939.
Li, W.F., Costa, L.G., Richter, R.J., Hagen, T., Shih, D.M., Tward, A., Lusis, A.J., Furlong, C.E.,
2000. Catalytic efﬁciency determines the in-vivo efﬁcacy of PON1 for detoxifying
organophosphorus compounds. Pharmacogenetics 10, 767–779.
Lockridge, O., Schopfer, L.M., 2010. Review of tyrosine and lysine as new motifs for
organophosphate binding to proteins that have no active site serine. Chem. Biol.
Interact. 187, 344–348.
Ma, T., Chambers, J.E., 1994. Kinetic parameters of desulfuration and dearylation of
parathion and chlorpyrifos by rat liver microsomes. Food Chem. Toxicol. 32,
763–767.
Mackness, B., Durrington, P., Povey, A., Thomson, S., Dippnall, M., Mackness, M., Smith,
T., Cherry, N., 2003. Paraoxonase and susceptibility to organophosphorus poisoning
in farmers dipping sheep. Pharmacogenetics 13, 81–88.
McConnell, R., Cedillo, L., Keifer, M., Palomo, M.R., 1992. Monitoring organophosphate
insecticide-exposed workers for cholinesterase depression. New technology for
ofﬁce or ﬁeld use. J. Occup. Med. 34, 34–37.
Motti, C., Dessi, M., Gnasso, A., Irace, C., Indigeno, P., Angelucci, C.B., Bernardini, S.,
Fucci, G., Federici, G., Cortese, C., 2001. A multiplex PCR-based DNA assay for the
detection of paraoxonase gene cluster polymorphisms. Atherosclerosis 158, 35–40.
Ngai, W., Ames, R.G., Wisniewski, J., Fan, A.M., 2002. Guidelines for physicians who
supervise workers exposed to cholinesterase-inhibiting pesticides, 4th ed. California
Environmental Protection Agency (EPA) Ofﬁce of Environmental Health Hazard
Assessment.
Pond, A.L., Chambers, H.W., Coyne, C.P., Chambers, J.E., 1998. Puriﬁcation of two rat
hepatic proteins with A-esterase activity toward chlorpyrifos-oxon and paraoxon.
J. Pharmacol. Exp. Ther. 286, 1404–1411.
Povey, A.C., 2010. Gene–environmental interactions and organophosphate toxicity.
Toxicology 278, 294–304.
Povey, A.C., Mackness, M.I., Durrington, P.N., Dippnall, M., Smith, A.E., Mackness, B.,
Cherry, N.M., 2005. Paraoxonase polymorphisms and self-reported chronic
ill-health in farmers dipping sheep. Occup. Med. (Lond) 55, 282–286.
Prabhavathy Das, G., Jamil, K., 2009. Human serum paraoxonase gene polymorphisms
and association with chronic symptoms of pesticide toxicity in Indian farmers.
Toxicol. Environ. Chem. 91, 177–185.
Richter, R.J., Furlong, C.E., 1999. Determination of paraoxonase (PON1) status requires
more than genotyping. Pharmacogenetics 9, 745–753.
Ruark, C.D., Hack, C.E., Robinson, P.J., Gearhart, J.M., 2011. Quantitative structure–activity
relationships for organophosphates binding to trypsin and chymotrypsin. J. Toxicol.
Environ. Health A 74, 1–23.
Sklan, E.H., Lowenthal, A., Korner, M., Ritov, Y., Landers, D.M., Rankinen, T., Bouchard,
C., Leon, A.S., Rice, T., Rao, D.C., Wilmore, J.H., Skinner, J.S., Soreq, H., 2004. Acetyl-
cholinesterase/paraoxonase genotype and expression predict anxiety scores in
Health, Risk Factors, Exercise Training, and Genetics study. Proc. Natl. Acad. Sci.
U. S. A. 101, 5512–5517.
Sultatos, L.G., 1994. Mammalian toxicology of organophosphorus pesticides. J. Toxicol.
Environ. Health 43, 271–289.
Sultatos, L.G., Murphy, S.D., 1983. Kinetic analyses of the microsomal biotransformation
of the phosphorothioate insecticides chlorpyrifos and parathion. Fundam. Appl.
Toxicol. 3, 16–21.
Timchalk, C., Kousba, A., Poet, T.S., 2002. Monte Carlo analysis of the human
chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based
pharmacokinetic and pharmacodynamic (PBPK/PD) model. Toxicol. Lett. 135,
51–59.nce cholinesterase activity in Egyptian agricultural workers exposed
016/j.taap.2012.08.031
